Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Tax Provisions for 16 consecutive years, with $221.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Tax Provisions rose 163.38% year-over-year to $221.5 million; the TTM figure through Mar 2026 stood at $827.4 million (up 20.14% YoY), while the FY2025 annual figure was $690.0 million, down 12.0% from the prior year.
• Tax Provisions came in at $221.5 million for Q1 2026 at Vertex Pharmaceuticals, up from $139.9 million in the prior quarter.
• The five-year high for Tax Provisions was $257.9 million in Q4 2022, with the low at $84.1 million in Q1 2025.
• Average Tax Provisions over 5 years is $198.0 million, with a median of $202.4 million recorded in 2024.
• Across the five-year window, Tax Provisions surged 292.36% in 2022 and slumped 53.15% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $257.9 million in 2022, then plunged by 30.67% to $178.8 million in 2023, then gained by 25.0% to $223.5 million in 2024, then plunged by 37.4% to $139.9 million in 2025, then soared by 58.33% to $221.5 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $221.5 million, $139.9 million, and $215.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.